Jeff Huber
Co-Founder at Triatomic Capital | Founding CEO of GRAIL | Former SVP of Google Ads, Apps, Maps & [x]
San Francisco Bay Area
Invests in
Sectors:
Locations:
Min Investment:
$250,000.00Max Investment:
$25,000,000.00Target Investment:
$10,000,000.00
Skills
Education
- Uo
- HB
Lists including Jeff
Investments
Betteromics
Total Funding: $20M
Chemify
Total Funding: $46M
Arsenal Bio
Total Funding: $220
Manifold Bio
Total Funding: $45M
Synapticure
Total Funding: $16M
Weta Digital
Total Funding: $10M
Cellanome
Total Funding: $5M
Aldevron
Total Funding: $250M
DeepSight
Total Funding: $10M
Agoric
Total Funding: $36M
Mammoth Biosciences
Total Funding: $260M
BitPay
Total Funding: $60M
LytEn
Total Funding: $10M
GRAIL
Total Funding: $240M
iMicrobes
Total Funding: $120K
Razorpay
Total Funding: $740M
Superhuman
Total Funding: $110M
UXPin
Total Funding: $2.7M
Work Experience
2022
Co-Founder & General Partner
2022
‘Applied AI’ in Deep tech, Health tech, & New economy // Helping great entrepreneurs build 'century-defining' businesses & technologies.
Board of Directors member (public)
2024
Bringing ivonescimab – a novel, first-in-class bi-specific antibody combining immunotherapy via PD-1 blockade and anti-angiogenesis via blocking VEGF in a single molecule – quickly and responsibly to clinical deployment, to help change cancer outcomes for millions of patients.
2024
Board of Directors member
2024
d-Matrix powers next generation compute for generative AI and large language models.
2022
Board of Directors member
2022
Manifold Bio is a next-generation protein therapeutics company pioneering an in-vivo biologics design platform.
2021
Board of Directors member (public)
2021
Zapata Computing is a quantum computing software & services company – powering quantum-enabled AI, machine learning & optimization for enterprises.
2021
Board of Directors member (public)
2021
Upstart's mission is to enable effortless credit based on true risk, enabled by AI/ML.
2020
Board of Directors member
2020
Mammoth Biosciences is building the CRISPR platform for the next generation of diagnostics, therapeutics, and cell/gene therapies.
2018
Board of Directors member
2018
Openwater is creating a new generation of imaging technologies to change how we read and write our bodies and brains.
2019
Chairman / Board of Directors member
2019
Genalyte is a healthcare analytics & diagnostics company improving patient outcomes with real-time point-of-care results.
2009
Board of Directors member (public)
2009
Member of Nomination & Governance (2010-2012) and Audit (2012-present) Committees. Helped focus EA’s transition from retail to online/cloud & mobile delivery. Valuation increased 600% over tenure.